MAP3K3 Antibodies

Mitogen-activated protein kinase kinase kinase 3 (MAP3K3)

Component of a protein kinase signal transduction cascade. Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators.

.

Gene Information

Human
Gene Name:	MAP3K3
Uniprot:	Q99759
Entrez:	4215

Family

Belongs to:
protein kinase superfamily

Alternative Names

EC 2.7.11.25; MAP/ERK kinase kinase 3; MAP3K3; MAPK/ERK kinase kinase 3; MAPKKK3; MAPKKK3MEKK 3; MEK kinase 3; MEKK3; mitogen-activated protein kinase kinase kinase 3

Molecular Weight

Mass (kDA):
70.898 kDA

Genomic Context

Human
Location:	17q23.3
Sequence:	17; NC_000017.11 (63622209..63696305)

Diseases

• Malignant Neoplasms
• Inflammation
• Tumor Angiogenesis
• Neoplasms
• Malignant Tumor Of Colon
• Carcinoma
• Mammary Neoplasms
• Pathologic Neovascularization
• Cell Transformation, Neoplastic
• Tissue Adhesions
• Malignant Neoplasm Of Breast
• Ovarian Neoplasm

• Psoriasis
• Congenital Abnormality
• Diabetes Mellitus
• Cavernous Hemangioma Of Brain
• Lymphopenia
• Nervousness
• Innate Immune Response

Interacting Proteins

• MAP2K5
• TRAF7
• YWHAB
• YWHAE
• YWHAG

• YWHAH
• YWHAQ
• YWHAZ

Pathways

• Cell Proliferation
• Angiogenesis
• Cell Differentiation
• Pathogenesis
• Rna Interference
• Cell Activation
• T Cell Activation
• Immune Response
• Vasculogenesis
• Cell Cycle Arrest
• Cell Cycle
• Oncogenesis
• Mitosis

• Cytokine Production
• Secretion
• Cell Migration
• Regulation Of Signal Transduction
• Tube Formation
• Adaptive Immune Response
• Keratinocyte Differentiation

PTMs

• Phosphorylation
• Ubiquitination

• Cleavage
• Methylation

• Dephosphorylation

Research Areas

• Angiogenesis
• Cancer
• Immunology
• Innate Immunity
• Protein Kinase

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/MAP3K3

Best Uses Of The MAP3K3 Marker From Boster Bio

Boster Bio Anti -MEKK3 MAP3K3 Antibody was tested for use in flow Cytometry, IP, IF applications. Boster Bio Anti–MEKK3 antibody can be used in flow cytometry as well as IP and IF applications. To validate their MAP3K3 antibodies, the company has performed extensive in-house testing.

Anti-MEKK3 MAP3K3 marker

Boster Bio's Anti MEKK3 MAP3K3/Antibody reacts to Human proteins. It is stable at 20°C for one-year, or six month if frozen. Boster Bio Anti MEKK3 MAP3K3 marker contains five milligrams BSA and 0.05 mgs of thimerosal. It recognizes amino acid sequences within the target protein. The peptide is also available separately.

Recent research has shown a link between increased MEKK3 gene expression in cancer and lower survival rates. Patients with higher MEKK3 levels had shorter median disease-free survival rates than those without nodal involvement and those with nodal recurrence. Patients with ESCC expressing high levels of MEKK3 had a lower overall survival rate. However, statistically, there was no significant relationship between anti MEKK3 expression and nodal state.

Semi-quantitative Scoring was used to evaluate the results. It measured the intensity and expression of MEKK3 proteins. Positive cells were epithelial cell with immunopositivity within the nucleus or in the cytoplasm. Each tissue section was scored according its percentage of immunostained tissues. The scores were 11-30%, 31-50%, and 51-70%.

MEKK3 protein expression was significantly increased in esophageal carcinomas. ESCC had significant MEKK3 cDNA cDNA expression. This marker can help in the treatment and prognosis for patients with ESCC. Although preliminary, these results could prove to be useful. And if you know your MEKK3 protein expression levels, you can use this test to detect this gene and monitor its level.

Although the MEKK3 protein may have therapeutic implications for esophageal carcinoma, it is not sufficient to detect high-risk lesions. In a study of 66 ESCC-patients, MEKK3 was detected in the distant dysplastic epithelia. However, it was not detected in matched normal esophageal ethelia. This observation supports the hypothesis MEKK3 may be involved in esophageal tumourigenesis.

The MAP3K3 & MAPKAP2 enzymes make up the MAPkinase pathway. Both MAPKAP2 and MAP3K3 are transcriptional co-activators and activate the PPARGC1A genes. Several miRs are responsible for reducing PPARGC1A, including miR-122. Many miRs target PPARGC1A, MED1and LCMT1A. These proteins could be responsible for the downregulation PPARGC1A.

High-affinity primary antibodies

MAP3K3 plays a critical role in the regulation of cell cycle and tumorigenesis. Its level is negatively correlated with a variety of important genes in vivo including MAPK6/ERK3, PCNA, BIRC5, TRIP13, and PCNA. However, the data from the Oncomine database suggests that the expression levels of MAP3K3 are not consistently decreased across different cancer types.

High-affinity primary antibodies against MAP3K3 have the highest sensitivity. The resulting assays were highly relevant in predicting the survival rates of patients with cancer. Therefore, if you want to perform your own assays, high-affinity primary antibodies are the best way to go.

MAP3K3 was linked to tumor development and immune cell activity. Recent studies show that lung cancer patients with higher MAP3K3 levels have better outcomes. This is believed to be due the balanced relationship between an active immune reaction and tumor cell growth within the tumor microenvironment. These results may eventually lead to the identification a new biomarker in lung cancer and immunotherapy.

MAP3K3 does not play a role in the ERK1/2, MAPK7 pathways but it plays a crucial part in tumor growth. It is involved in cell proliferation and migration, as well as invasion. It is also associated CDC25A (CCND1/2) and other cancer-related pathways. These findings are encouraging. They warrant further investigation. High-affinity antibody are the best use for the MAP3K3 marker at the moment.

6 diseases have MAP3K3 gene fusions, including breast and lung cancer. DNA changes that affect MAP3K3 expression are associated with a subset of lung cancers, although these are not linked to outlier mRNA expression. Further research is needed on which cells express MAP3K3 fusion genes. MAP3K3 gene fusions can also be associated with breast, prostate, and ovarian carcinomas.

A favorable survival rate for ADC patients is associated to MAP3K3 mRNA omissions. The study reported by Shedden et al. The study involved 471 and 221 ADC cases. qRTPCR was used for two independent datasets that confirmed MAP3K3 mRNA repression. The median value of MAP3K3 mRNA was used as a cutoff. To divide the patients into high- and low-expression groups, the authors used log rank analysis.

Clinical applications

Breast cancer has been linked to MAP3K3. MAP3K3 acts as a direct activator for the ERK1/2 pathway. Breast cancer can be caused by MAP3K3 overexpression. NB cells also show a reduced response rate to BETi treatment when MAP3K3 levels are high. This is the first time that a MAP3K3 marker has been used to determine the extent cancer-related MAP3K3 gene expression in patients.

In a study evaluating the prognostic role of MEKK3 overexpression in ESCC, researchers found that tumors with increased levels of MEKK3 were more likely to have advanced disease and a poor prognosis. The clinical applications of MAP3K3 in this disease will continue to be investigated. ESCC is difficult to diagnose due to the high levels of the MEKK3 gene.

To further understand MAP3K3's role in cancer, researchers identified a new miRNA called miR-3140-3p that targets the MAPK/ERK1/2 pathway. The miR-3140-3p targets the MAP3K3-ERK1/2 pathway and mapped miR-3140-3p to the gene BRD4. MiR-3140-3p reduced MAP3K3 activity in NB-resistant cells by affecting the expression of BRD4-MYCN.